– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...

Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot ...

Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection. The agent (Tecentriq Hybreza, ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

TG Therapeutics, Inc.'s Briumvi, a treatment for multiple sclerosis, faces competition from Roche's Ocrevus, which has shown positive results in a Phase 3 trial. Briumvi's intravenous administration ...